Certified by Founder
Lodge
AltPep
start up
United States
- Seattle, Washington
- 26/06/2023
- Series B
- $53,000,000
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.
Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
- Industry Biotechnology
- Website https://www.altpep.com/
- LinkedIn https://www.linkedin.com/company/altpep/
EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)